The Notch/Hes1 Pathway Sustains NF-κB Activation through CYLD Repression in T Cell Leukemia

Lluís Espinosa,1,12,* Severine Cathelin,2,12 Teresa D’Altri,1 Thomas Trimarchi,2 Alexander Statnikov,3 Jordi Guiu,1 Veronica Rodilla,1 Julia Inglés-Esteve,1 Josep Nomdedeu,4 Beatriz Bellosillo,5 Carles Besses,6 Omar Abdel-Wahab,7 Nicole Kucine,7,8 Shao-Cong Sun,9 Guangchan Song,10 Charles C. Mullighan,10 Ross L. Levine,7 Klaus Rajewsky,11 Iannis Aifantis,2,13,* and Anna Bigas 1,13,*

1Cancer Research Program, Institut Municipal d’Investigacions Mèdiques, (IMIM), Hospital del Mar, 08003 Barcelona, Spain
2Howard Hughes Medical Institute and Department of Pathology
3Center for Health Informatics and Bioinformatics and Department of Medicine
New York University School of Medicine, New York, NY 10016, USA
4Hematology Department, Hospital de Sant Pau, 08025 Barcelona, Spain
5Pathology Department
6Hematology Department
Hospital del Mar, 08003 Barcelona, Spain
7Human Oncology and Pathogenesis Program
8Department of Pediatrics
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
9Department of Immunology, The University of Texas MD Anderson Cancer Center, TX 77030, USA
10Department of Pathology, St. Jude’s Research Hospital, Memphis, TN 38105, USA
11Program of Cellular and Molecular Medicine, Children’s Hospital, and Immune Disease Institute, Harvard Medical School, Boston, MA 02115, USA
12These authors contributed equally to this work
13These authors contributed equally to this work
*Correspondence: iannis.aifantis@nyumc.org (I.A.), abigas@imim.es (A.B.), lespinosa@imim.es (L.E.)
DOI 10.1016/j.ccr.2010.08.006

SUMMARY
It was previously shown that the NF-κB pathway is downstream of oncogenic Notch1 in T cell acute lymphoblastic leukemia (T-ALL). Here, we visualize Notch-induced NF-κB activation using both human T-ALL cell lines and animal models. We demonstrate that Hes1, a canonical Notch target and transcriptional repressor, is responsible for sustaining IKK activation in T-ALL. Hes1 exerts its effects by repressing the deubiquitinase CYLD, a negative IKK complex regulator. CYLD expression was found to be significantly suppressed in primary T-ALL. Finally, we demonstrate that IKK inhibition is a promising option for the targeted therapy of T-ALL as specific suppression of IKK expression and function affected both the survival of human T-ALL cells and the maintenance of the disease in vivo.

INTRODUCTION
NF-κB is an important regulator of cell survival, proliferation and differentiation and is frequently involved in malignant transformation (Karin, 2006). NF-κB is mainly activated in response to proinflammatory stimuli such as TNFα or IL1β, components of pathogenic bacteria and viruses, or after TCR signaling in T-lymphocytes. Regardless of the activation of specific receptors that associate to different effectors, canonical NF-κB signaling invariably leads to the activation of IκB kinase (IKK) complex composed of two catalytic and one regulatory subunits called IKKα, IKKβ, and NEMO (IKKγ), respectively. The main target of activated IKK complex is the NF-κB inhibitor, IκB, that it is rapidly phosphorylated in specific serine residues thus targeting the protein for ubiquitination, leading to proteasomal degradation. Degradation of IκB is sufficient to induce the nuclear translocation of the transcription factor that results in specific gene activation (Vallabhapurapu and Karin, 2009). IκBζ itself is one of the main transcriptional targets for NF-κB activity thus providing an efficient mechanism for signal termination

Significance
Although aberrant activation of the Notch pathway is a recurring event in T-ALL, the downstream signaling effects of this activation are poorly defined. Our work demonstrates that the Notch-Hes1-CYLD-IKK axis plays a crucial role in this type of leukemia, and that blocking NF-κB (or the IKK kinase) is sufficient to eliminate leukemic cells carrying activating Notch mutations. These findings suggest that NF-κB targeting could be a key component of successful future T-ALL clinical trials.
(Hoffmann et al., 2002). However, other mechanisms are required to maintain the nonactive state of NF-κB in the absence of stimulation but also to attenuate the signal after chronic stimulation of the pathway. They involve the deubiquitination enzymes A20 and CYLD, which remove the activator K63 ubiquitin chains from different elements of the NF-κB signalosome (Brummelkamp et al., 2003; Reiley et al., 2007; Trompouki et al., 2003; Wertz et al., 2004).

Despite the huge amount of gathered data on NF-κB activation, not much is known about the crosstalk of NF-κB with other signaling pathways, including pathways that control tissue differentiation like the Notch cascade. Notch receptors are crucial regulators of cell differentiation in multiple systems (reviewed by Egan et al., 1998). Activation of Notch by Jagged or Delta ligands results in the cleavage of the intracellular fragment of the receptor by a γ-secretase activity (Mumm et al., 2000). Once released from the extracellular part of the molecule, the intracellular cleaved Notch translocates to the nucleus to bind the ubiquitous RBPjκ factor and to activate transcription of a number of target genes, including the Hes family of transcription factors (Iso et al., 2003; Jarriault et al., 1995). The classical function of Hes family proteins is the transcriptional repression of prodifferentiation genes by direct interaction with specific sequences of their promoters or by the association with other bHLH factors and combinatorial DNA binding (Kageyama and Ohtsuka, 1999; Kuroda et al., 1999). The Notch pathway was recently shown to be oncogenic in a wide variety of cancers, most notably in T cell acute lymphoblastic leukemia (T-ALL), a devastating pediatric tumor arising by the transformation of hematopoietic progenitor cells. In this disease, the majority of patients harbor either activating mutations of Notch1 or inactivating mutations affecting negative regulators of the Notch pathway (Afantis et al., 2006).

Recent evidence has suggested an interaction between Notch and NF-κB, more specifically in the context of cell transformation. Crosstalk between the Notch and NF-κB pathways have been proposed in human T-ALL and in mouse models of T cell leukemia (Screpanti et al., 2003; Shin et al., 2006; Vilimas et al., 2007). More specifically, we have previously shown that Notch activation can induce the expression of a large fraction of classical NF-κB gene targets in T cell progenitors. We have also demonstrated that this Notch-induced NF-κB activation requires both the transcriptional activity of Notch and the function of the IKK complex (Vilimas et al., 2007). However, these studies failed to provide a definitive demonstration that this interaction can be translated into a new therapeutic tool. Moreover, neither the mechanism explaining the ability of Notch to impinge on IKK (and thus NF-κB) activation nor the importance of IKK activation for the maintenance of T-ALL in vivo was addressed. These key issues could introduce NF-κB inhibition as an effective therapy for the treatment of T-ALL and are all addressed here.

RESULTS

Oncogenic Notch Induces NF-κB Activation both In Vitro and In Vivo

We attempted to visualize in vivo the Notch-induced NF-κB activation using an animal model of T-ALL. We combined an established transplantation model with a NF-κB-dependent in vivo luciferase reporter strain (κBLuc) to measure the activation of this pathway. We transplanted ICN1“κBLuc” progenitors in irradiated hosts and monitored the progression of the disease and the activation of the reporter using both FACs analysis and in vivo bioluminescence. Disease was induced as evidenced by the appearance of leukemic CD4+CD8+ blast cells in the peripheral blood (not shown). Early during T-ALL, visual induction of NF-κB activation was undetectable, probably due to the low number of transformed cells at this stage of the disease. However, NF-κB activity increased rapidly and was readily detectable 3 weeks post-cell transplantation with “hotspots” in tissues containing lymphoid cells, including the thymus and bone marrow areas (Figure 1A).

To further prove that Notch was responsible for induction of NF-κB activation, we used a distinct, recently generated animal model of the disease that does not require transplantation. In this model, the oncogenic ICN1 mutant is “knock-in” the EF1α locus and induced by Cre-recombinase expression (Buonamici et al., 2009). ICN1 expression rapidly induced T-ALL (Figure 1B) that overexpressed nuclear Notch1-IC and its target gene Hes1 (Figures 1C and 1D). To test whether NF-κB was activated in the leukemic cells, we sorted the CD4+CD8+ population and used a conventional EMSA approach. As shown in Figure 1E, this leukemic population showed significant NF-κB activation, as indicated by the increased DNA-binding activity. Antibody shift experiments demonstrated a predominance of p50-p50 (Nfκb1:Nfκb1) and p50:p65 (Nfκb1:RelA) dimers.

To support that Notch is responsible for promoting NF-κB activity in T-ALL cells, we measured the activation of a virally-driven NF-κB-dependent EGFP reporter in a representative human cell line (KOPT-K) that carries Notch mutations (O’Neil et al., 2007). We either kept the cells untreated or treated them with gamma-secretase inhibitors (GSI). Inhibition of the Notch pathway by GSI reduced the activation of the NF-κB-dependent EGFP reporter, the expression of the Notch-target genes Hes1, Deltex1, the NF-κB target Bcl2/IA1, as well as NF-κB DNA binding activity (Figures S1A–S1C).

These combined experiments support the hypothesis that NF-κB is targeted by Notch and demonstrate that this crosstalk between the two pathways takes place also in vivo models of T-ALL. We were thus curious to see whether this in vivo Notch-induced NF-κB activation leads to the activation of a subset of genes that have been characterized as direct or indirect NF-κB targets. We have thus carried out a meta-analysis of the transcriptional profiling comparisons between “control” and “leukemic” T cells carried out by Li et al. (2008). As shown in Figure 1F, a large number of known NF-κB target genes, as proposed by multiple studies, were significantly induced in the CD4+8+Notch1-IC+ tumor samples. To further identify genes induced in leukemia that are direct NF-κB targets, we have combined our analysis to a recent report that combined whole-genome chromatin immunoprecipitation data (ChIP-seq) and RNA-sequencing data, identifying NF-κB p65 direct transcriptional targets (Kasowski et al., 2010). As shown in Figure S1D available online, we identified a significant number of NF-κB direct targets that are significantly upregulated in T-ALL cells. The combination of these data strongly suggest that a NF-κB gene expression “signature” is characterizing leukemic T cells in Notch-induced T-ALL.
Hes1 Induces NF-κB Activity and Nuclear Translocation of p65 by Facilitating IkBα Degradation

Next, we addressed the mechanism of Notch-induced NF-κB activation. To answer this question, we measured the activity of a NF-κB-dependent reporter in response to ectopic expression of ICN1 or its main target Hes1. We found that ectopic expression of doxycycline-inducible Hes1 (Figure 2A) or non-inducible flag-Hes1 resulted in a dose-dependent activation of NF-κB, comparable to that induced by ICN1 (Figure S2). Activation of NF-κB was concomitant with the nuclear accumulation of p65 in Hes1 expressing cells, as detected by immunofluorescence (Figure 2B).

We analyzed whether modification of the IkBα protein levels were responsible for the increased NF-κB-transcriptional activity.
induced by Hes1. We found that ectopic Hes1 expression correlated with a reduction in IkBα protein levels in the absence of stimulation that was further enhanced by chronic TNFα treatment (Figure 2C). Most importantly, IF staining of HEK293T cells demonstrated that after TNFα treatment there was a complete absence of endogenous IkBα in cells expressing ectopic Hes1, whereas the rest of the cells have already resynthesized IkBα (Figure 2D).

As Hes1 is a well-characterized transcriptional repressor (Iso et al., 2003), we speculated that Hes1 was regulating IkBα at the level of transcription. To test this possibility, we carried out qRT-PCR from cells transfected with the control vector or the inducible Hes1 construct, untreated or treated with TNFα and/or doxycycline as indicated. We found that Hes1 expression did not exert any inhibitory effect on either basal or TNFα-induced IkBα transcription, but rather increased IkBα transcription as it is an NF-κB target (Figure 2E). These results suggested that Hes1 was modulating IkBα protein stability. In agreement with this, incubation with the proteasomal inhibitor MG132 or mutation of lysines 21 and 22 of IkBα into arginine, which are required for K48-linked ubiquitination (Rodriguez et al., 1996), completely abrogated the effects of Hes1 on IkBα levels (Figure 2F and 2G). These results demonstrated that Hes1 is able to induce IkBα degradation, which results in increased NF-κB activity.

**Hes1 Facilitates IkBα Degradation by Modifying IKK Activity**

As it is well established that IkBα degradation is regulated by the IKK complex, in response to the specific phosphorylation by IKKβ, we tested the effect of the IKKβ inhibitor BAY65-5811 on Hes1-induced degradation of IkBα. Inhibition of the IKK activity completely blocked the phosphorylation of IKK and the degradation of IkBα induced by ectopic expression of Hes1 in the presence of chronic TNFα treatment (as detected with the specific antibody recognizing phosphorylated serines 180 and 181 of HA-IKKα and IKKβ, respectively) (Figure 3A). Next, we tested whether hess1 expression affected the phosphorylation/activation status of IKKα or β that are the catalytic subunits of the IKK complex. Figure 3B shows that doxycycline-inducible Hes1 expression significantly and specifically increased the amounts of active/phosphorylated HA-IKKβ but not HA-IKKα. As a control we show that this effect was not induced by doxycycline alone (Figure 3A3). To further demonstrate the requirement of IKKβ in the Hes1-induced degradation of IkBα, we expressed HA-IkBα together with the inducible Hes1 construct in IKKβ-deficient MEFs. As shown in Figure 3C, Hes1 was not sufficient to induce IkBα degradation in cells lacking IKKβ, whereas reintroduction of IKKβ restored the ability of Hes1 to reduce IkBα levels. Finally, ectopic expression of the dominant negative form of IkBα, which blocks the activity of IKKβ, completely blocked the Hes1-induced degradation of IkBα (Figure 3D).
TAK1 (TAK1K63W), the specific kinase that activates IKKβ, was sufficient to block the IκBα-degradation imposed by Hes1 (Figure 3D). These results indicate that Hes1 induces IκBα degradation by facilitating the activation of the IKK complex in both basal conditions and after TNFα treatment, and that this effect takes place upstream of IKKβ phosphorylation by TAK1.

**Hes1 Is Responsible for Sustaining IKK/NF-κB Activity in Notch-Dependent Leukemia**

Based on these results, we speculated that the NF-κB activation that occurs in T-ALL with aberrant Notch activity might be mediated through Hes1. We confirmed that Notch1 activation (as detected by the Val1744 antibody) was mainly, although not exclusively, found in T-ALL lines, inversely correlating with the protein levels of IκBα (Figure S3B). To determine the contribution of Hes1 to the regulation of IκBα in T-ALL, we infected Jurkat cells with a lentiviral construct containing the shRNA against Hes1 or the control shRNA. Hes1 knockdown resulted in increased IκBα levels in noninduced cells and even more significant after chronic TNFα treatment (Figure 4A). Comparable results were obtained by inhibiting Notch activation in Jurkat cells with GSI (Figure 4B). Moreover, chronic activation of the endogenous IKK kinase complex after TNFα treatment was eliminated in cells with reduced Hes1 expression (Figure 4C). Next, we tested whether NF-κB activation was regulated by Hes1 in these cells and found a reduction in the levels of several NF-κB-target genes such as Bcl2A1 or cIAP2 by knocking down Hes1 in both Jurkat and most important, in primary human T-ALL cells (Figures 4D and 4E). Identical effects were obtained in Jurkat cells treated with GSI (Figure S4A). To study the functional relevance of Hes1 in cells containing active Notch ex vivo, we transduced lineage-depleted bone-marrow cells with a lentiviral vector expressing the oncogenic ICN1 alone or together with the Hes1-shRNA construct. Cells were serially plated every week and counted as an estimated measure of self-renewal capacity (Lavau et al., 1997) (Figure 4F). We found that ICN1-expressing cells exhibited a higher clonogenic capacity than the cells coexpressing the Hes1-shRNA as indicated by the increased number of colonies in these cultures (Figure 4G). Importantly, ICN1-transduced progenitors were able to produce increasing number of CD3+ cells when plated on OP9-Dll1 stroma compared to Hes1-shRNA-expressing cells (Figure 4H and Table S1). Moreover, in the absence of Hes1, cells expressing ICN1 showed an elevated number of apoptotic cells as measured by Annexin-V binding (Figure 5A) concomitant with a decrease in the expression of the prosurvival genes Bcl2A1 and cIAP2 (Figure 4I). To determine whether NF-κB provided prosurvival signals in ICN1-transduced cells, we plated these cells in the presence of the IKK inhibitor BAY65-5811. In these conditions, expression of oncogenic ICN1 was not sufficient to support colony and cell growth (Figure 4J).

**The Expression of the Deubiquitinase CYLD Is Suppressed in Human T-ALL**

Because our results indicated that Hes1 was able to maintain IKK complex activation in T-ALL and we mapped this function upstream of TAK1, we tested whether the expression of the negative regulators of IKK activity, CYLD and A20, was decreased in human T-ALL. In this screen we included a group of 13 healthy control samples (9 whole peripheral blood [WPB] and 4 purified WPB) and 33 WPB samples from T-ALL patients containing >60% of leukemic blasts, except sample number 18 with 44% leukemic cells (for details see Table S2). Using qRT-PCR we found that mRNA levels of both deubiquitinating enzymes were significantly decreased in the leukemic samples compared to the normal controls (p < 0.001 for CYLD and p < 0.001 for A20 using Student’s t test) concomitant with a significant increase in the expression of Hes1 (p = 0.001) (Figure 5A). Further meta-analysis of ALL gene expression databases showed that CYLD levels in T-ALL are significantly lower than in any B-ALL category (not shown). Next, we tested whether there is an inverse correlation between Hes1 and either CYLD or A20 genes in T-ALL by using Hes1-specific shRNA-mediated knock-down. Reduction of Hes1 levels resulted in a pronounced increase in the mRNA of CYLD whereas A20...
levels remained unaffected (Figure 5B). In contrast, overexpression of Hes1 in HEK293T cells resulted in a reduction in the levels of CYLD mRNA (Figure 5C) and protein (Figure 5D) associated with lower levels of IkBa, being this effect more dramatic after chronic treatment with TNF (Figure 5D). We next tested whether Hes1 protein levels inversely correlated with CYLD protein levels in different T-ALL cell lines containing Notch1 mutations. As shown in Figure 5E, CYLD levels were reduced in T-ALL cells when compared to B cell (Nalm6, RAJI, and RPMI1783) or myeloid leukemia cell line (HL60) concomitant with variable, but higher levels of Hes1 protein. Importantly, inhibition of Notch1 by GSI resulted in an increase of both protein (Figure S5) and mRNA (not shown) levels of CYLD in these cells.

**The Notch Pathway Directly Controls CYLD Expression through Hes1**

These data suggested that CYLD expression is kept suppressed in T-ALL, leading to an enhancement of IKK activity. To test whether the Notch pathway and specifically Hes1 was directly repressing CYLD transcription, we used the Genomatix software to identify putative Hes1 binding sites, and found three distinct N-box consensus sites in the promoter and 5’UTR of the CYLD gene (Figure 6A, denoted as PRO1 and PRO2). Using a conventional ChIP assay in human Hes1+ T-ALL cells and a Hes1 antibody followed by PCR with specific primers flanking the identified putative N-box sites, we were able to show that endogenous Hes1 binds to the predicted PRO2 site in the CYLD 5’UTR (Figure 6B) and this association was lost after Hes1 knock-down (Figure 6C) as measured by qPCR. Ectopic expression of CYLD completely reverted the clonogenic growth of lineage negative BM cells transduced with ICN1 whereas downregulation of CYLD was sufficient to increase the number of colonies in this assay (Figure 6D). Consistent with these results, we found that ectopic expression of CYLD is sufficient to block Notch-induced activation of an NF-kB-dependent reporter in HEK293T (Figure S6A). Moreover, the capacity to produce CD3+ T cells by ICN1-transduced progenitors in coculture on OP9-D11 stroma is partially mimicked by CyD-shRNA-expressing cells and lost in cells coexpressing ICN1 and CYLD (Figure 6E and Figure S6) To further support the notion that CYLD expression in T-ALL is controlled by direct transcriptional repression by Hes1, we have quantified CpG methylation at the CYLD promoter using the previously introduced human T-ALL samples. As shown in Figure 6F, there was no evidence of promoter hypermethylation suggesting that it is unlikely that DNA methylation can explain by itself the suppression of CYLD expression. These observations suggest that suppression of CYLD enhances the activity of the IKK kinase and the nuclear localization of NF-kB transcription factors. To directly test this hypothesis, we have totally eliminated CYLD expression in T-ALL using an animal model of CYLD deficiency (Reiley et al., 2006). As shown in Figures S6B–S6D, CYLD deletion is sufficient to significant enhance nuclear NF-kB activity in T-ALL cells as quantified by EMSA. All these observations strongly suggest that Hes1 sustains IKK complex activation and maintains the tumor phenotype in T-ALL by directly repressing CYLD expression and function.

**Targeted IKK In Vitro Silencing Affects the Growth of Human T-ALL Lines**

Our data so far suggest that targeting the IKK complex could be effective in the treatment of T-ALL. We have shown previously that the proteasome inhibitor bortezomib could affect T-ALL cell line growth (Vilimas et al., 2007). As Bortezomib is not a specific NF-kB inhibitor (Hideshima et al., 2009), we have now tested the effects of a cell permeable peptide (NEMO binding domain) that specifically blocks IKK by disrupting the interaction of NEMO to IKK (May et al., 2000) on several (total of nine) T-ALL cell lines that have an active Notch pathway present and exhibit NF-kB activation. These human T-ALL cells harbor activating Notch1 mutations. As shown in Figure 7A, the NBD peptide was able to efficiently inhibit nuclear NF-kB binding activity in T-ALL lines. Interestingly, silencing NF-kB led to specific biological effects, as shown by the rapid induction (24 hr) of apoptosis as determined by Annexin-V binding and caspase-3 activation (Figures 7B and 7C). No effects on cell cycle progression were noted suggesting that IKK inactivation is predominantly affecting cell survival (not shown).

To better understand the molecular effects of IKK inhibition in vitro we used these five T-ALL lines to study transcriptome changes 16 hr after the addition of the NBD peptide. The initial conclusion from these experiments is that although the response to NBD treatment was uniform, gene expression changes were both general and cell-line specific (Figure 7D and Figure S7A). All five cell lines showed signs of induction of cell death characterized by the upregulation of Bcl2L11 (Bim), Bik, and Foxo3, in agreement with their apoptotic phenotype, and an inhibition of NF-kB target genes (such as Myc, Ptpn6, Pnkp, and Gpx1). Interestingly, another uniform target of IKK inhibition was the Notch pathway itself (including Hes1, Hes4, Notch1, Notch3, and Dtx1) suggesting a mechanism of feedback inhibition. Using qRT-PCR we have verified the NBD-dependent regulation of several of these genes (Figure S7B). These findings suggested that IKK signaling was essential for disease maintenance and proposed that IKK inhibition could be a potential therapeutic tool in T-ALL.

**IKK Complex Activity Is Essential for the In Vivo Maintenance of T-ALL**

One of the key questions in cancer treatment is whether therapeutic targeting of a single signaling pathway is sufficient to affect tumor maintenance and progression. To address this key question in vivo we combined the Notch-dependent leukemia model with an inducible IKK (Nemo) deficiency (Mx1-cre*Nemo(−/−)) model. Bone marrow stem and progenitor cells purified from Mx1-cre-inducible NEMO-deficient mice were transduced with ΔEN1-luciferase or EGFP-expressing retroviruses and transplanted into irradiated recipients. Two weeks posttransplantation, once the disease had been established as indicated the presence of double CD4+CD8+ lymphocytes in the peripheral blood (Figures 8A and 8B) and the expansion of the donor cells as detected by in vivo bioluminescence (Figures 8C and 8D), Nemo expression (and thus canonical NF-kB activation) was silenced by inducing the expression of Cre recombinase using poly-l-lysine injections (Kuhn et al., 1995). As shown in Figures 8B–8F, deletion of Nemo very efficiently...
Figure 4. Inhibition of Hes1 in Cells with Active Notch1 Prevents NF-κB Activity Leading to Increased Apoptosis

(A) Jurkat cells transduced with scrambled shRNA or Hes1-shRNA (80%–90% reduction in Hes1 protein levels) were analyzed for the levels of IκBα protein during TNFα treatment.

(B) IκBα is restored in the presence of GSI (L685,458).

(C) Levels of P-IKK in control and Hes1 knockdown cells by western blot.

(D) Expression of NF-κB-target genes by qRT-PCR in Jurkat transduced with the control or Hes1-shRNA lentivirus.

(E) Primary human T-ALL leukemic cells transduced with the control or Hes1-shRNA lentivirus.

(F) Experimental design to test the contribution of Hes1- to ICN1-transduced cells.

(G–I) Primary mouse Lin− bone marrow progenitors transduced with the indicated lentivirus. (G) Colonies obtained from serial replatings on methylcellulose were counted. (H) T cell differentiation was determined by CD3 expression after 7 days in coculture on OP9-Dll1. One representative experiment out of three is shown.
reverted disease progression as judged by both the significant decrease in luminescence (Figures 8C and 8D) and the disappearance of transformed CD4⁺CD8⁺ T cells from the peripheral blood of the treated animals (Figures 8A and 8B) and T cell infiltration in the spleen and liver (Figure 8F). In agreement to the effects of IKK inhibition on T-ALL cell lines, IKK/Nemo deletion lead to rapid induction of leukemic cell apoptosis (Figure 8E).

Consistent with these phenotypic observations, pI-pC treated *Nemo*wt/wt, *MxCre*+ expressing animals succumbed significantly faster than their pI-pC treated *Nemo*fl/fl, *MxCre*+ counterparts. However, if the treatment was not continuous, the disease was able to relapse and eventually kill the animals (Figure 8G). To determine whether the reappearance of the disease was due to the expansion of a small cell population in which Nemo was not deleted, we sorted leukemic cells, 61 days posttransplant (approximately 40 days after the last pI-pC injection) and tested them for the presence of Nemo. Further supporting the essential function of IKK signaling in T-ALL leukemias, the purified cells were bearing the “undeleted” NEMO allele (Figure S8A) and showed a significant increase of NF-κB DNA-binding activity in the nucleus (Figure S8B). These studies are the first to demonstrate that IKK activity is essential for the maintenance of T-ALL and open the way for inhibiting the IKK complex as a therapeutic target for patients with already established T-ALL.

DISCUSSION

Our studies demonstrate that the transcriptional repressor Hes1, a target of oncogenic Notch1, is able to induce the activation of the NF-κB pathway in human T-ALL lines and animal models of the disease. Moreover, they show that IKK/NF-κB signaling is essential for the maintenance of the disease, as T-ALL cells that are unable to activate the IKK kinase complex rapidly enter apoptosis. As Notch1 mutations or pathway hyper-activation are found in the vast majority of T-ALL patients, our findings are clinically important as they could be translated to either as single agent therapy targeting IKK (or NF-κB) activation or combinatorial drug treatments that could in parallel target additional elements of the Notch pathway.

The presented studies identify a previously unidentified mechanism of Notch-induced NF-κB activation in T-ALL. We show that *Hes1* is a key mediator of Notch-induced transformation by targeting the deubiquitinase CYLD, a negative regulator of IKK activity. Our experiments demonstrate that *Hes1* expression is sufficient to enhance NF-κB activity and this effect maps upstream of IκBα degradation, IKK phosphorylation, and TAK1 activity. A significant portion of these effects can be attributed to the suppression of CYLD expression by Hes1. In agreement with this notion, we have identified CYLD as a direct target for Hes1 repression. CYLD is a deubiquitinating enzyme that was originally identified as a tumor suppressor and is mutated in familial cylindromatosis (Bignell et al., 2000). More recently, CYLD inhibition has been associated with other tumors such as melanoma (Massoumi et al., 2009) and breast (Hutti et al., 2009). Although previous to this report, there was no information about an involvement of CYLD in leukemia, abnormal
lymphopoiesis in CYLD-deficient animals had been reported (Reiley et al., 2006). This abnormal differentiation observed in the CYLD-deficient mice was initially associated with a defect in Lck kinase activation in response to TCR signaling, however it was later demonstrated that CYLD is also responsible for TAK1 deubiquitination resulting in the inactivation of the NF-κB pathway in T-lymphocytes (Reiley et al., 2007). Other well-characterized CYLD substrates that participate in the NF-κB signaling include TRAF2, Bcl3, and IKKγ/NEMO. We demonstrate here that CYLD expression is downregulated in T-ALL cell lines and primary samples, and that knocking down Hes1 expression in these cells results in increased CYLD levels and attenuation of the NF-κB signaling. Interestingly, Hes1-mediated suppression appears to be the preferred mode of regulation as no inactivating mutations or CYLD promoter hyper-methylation were detected in human T-ALL (data not shown).

Figure 6. Hes1 Directly Represses CYLD Transcription in T-ALL

(A) Scheme of the CYLD promoter indicating the putative Hes1 binding sites.
(B) Detection of the CYLD PRO-2 Hes1 binding site by PCR using the indicated antibodies.
(C) Relative enrichment of the CYLD promoter quantified by qPCR from ChIP with anti-Hes1 antibody in Jurkat T-ALL cells transduced with scrambled or Hes1-shRNA. Error bars denote ± standard deviation.
(D) Primary mouse lineage-negative bone marrow progenitors were transduced with the indicated lentivirus and colonies obtained from serial replating on methylcellulose were counted every week.
(E) Representative FACS analysis from week 3 progenitors after 7 days on OP9-Dll1 stroma.
(F) EpiTYPER methylation analysis showing no significant hypermethylation of the CYLD promoter. The heat map illustrates the range of methylation percentages, with red indicating 0% methylation and yellow indicating 100% methylation. Numbers along the top indicate CpG dinucleotide, patient sample numbers are listed along the vertical axis (p denotes the identity of the patient as presented in Figure 5A). Samples are run in duplicate. Two primers were run for each region. The positive control, IVD, has near 100% methylation, whereas the negative control, WGA, is unmethylated.

See also Figure S6.
mature thymocyte (Schmidt-Supprian et al., 2003). Consistent with this notion, silencing NEMO/IKK was sufficient to inhibit NF-κB activation in our animal model of ICN1-dependent T-ALL. We have previously shown that IKK can be activated constitutively in T-ALL (Aifantis et al., 2009). We demonstrate here that in T-ALL, IKK can be induced to affect the survival of both Notch1 and Notch3 overexpressing T cell leukemia lines (Mandal et al., 2005). We have also previously shown that Bim is expressed in low amounts in T cell leukemia and that it controls early T cell death induction (Mandal et al., 2008), making this molecule a putative therapy target.

Another important point made by our studies is that Notch/Hes1 activation is targeting the canonical NF-κB pathway in T-ALL. NEMO is a regulatory subunit of IKK complex, which is responsible for activation of canonical NF-κB signaling pathway. The T lineage-specific deletion of NEMO prevents the generation of peripheral T cells due to apoptotic death of CD44+CD8+ thymocytes (Schmidt-Supprian, 2003; Davis et al., 2001; Davis et al., 2001; Mandal et al., 2005). It is thus conceivable that the tumors have basal NF-κB activation and suppression of the negative regulator of the IKK complex (CYLD) further boosts pathway activation.

Although the role of NF-κB in leukemogenesis has been previously reported (Davis et al., 2001), several recent studies in tumors as diverse as diffuse large B cell lymphoma (DLBCL) (Compagno et al., 2009; Kato et al., 2009) or lung adenocarcinoma (Compagno et al., 2009; Kato et al., 2009; Meylan et al., 2009) suggest that the possibility to target this pathway in cancer therapy should be re-evaluated. In agreement with our findings, alterations in different elements of the NFκB pathway, including the enzymes A20 and CYLD, were found to be responsible for activating NF-κB in multiple myeloma and DLBCL, upstream of the IKK complex (Annunziata et al., 2007; Compagno et al., 2009; Kato et al., 2009; Meylan et al., 2009). In lung cancer cells with mutated K-ras, NF-κB is activated by the noncanonical TBK1/IKK interaction (Barbie et al., 2009) and blocking IKK activity reduces tumor growth in vivo (Meylan et al., 2009). We demonstrate here that in T-ALL, IKK can be activated by the Notch-Hes1-CYLD signaling cascade. However, whatever the trigger, the outcome is identical: activation of IKK, degradation of IκBα and nuclear translocation of the NF-κB factor, which provides the base to consider that pharmacological targeting of the IKK/NF-κB pathway could be a promising future treatment of a wide spectrum of tumors. The recent development of chemical inhibitors of the IKK complex, drugs that are currently in clinical trials for inflammatory disease, will enable us to test this hypothesis in future treatment protocols.

**EXPERIMENTAL PROCEDURES**

**Mice and Animal Procedures**

CS7BL/6, or BALB/C mice were purchased from Jackson Laboratories and Taconic Farms. BALB/C-Tg(Notch-1)268–281, September 14, 2010 © 2010 Elsevier Inc. 277
Figure 8. The NEMO/IKK Complex Activity Is Essential for the Maintenance of T-ALL In Vivo

(A and B) Peripheral blood FACS analysis using CD4, CD8, and Ly5.2 antibodies at different time points posttransplantation.
(C) ΔEN1-luc Nemowt/wt, Mx-Cre and ΔEN1-luc Nemof/f, Mx-Cre chimeras were monitored before and after pl-pC injections using in vivo imaging system (IVIS) to quantify luciferase intensity. Two weeks posttransplantation and before any deletion of NEMO, both chimeras harbored homogenous tumor load. Once this was verified mice were injected by pl-pC.
(D) Quantification of luciferase intensity (dorsal and ventral) at different time points. Error bars denote ± standard deviation.
(E) Determination of apoptotic cells gated on GFP+ cells 5 days after plpC injections in ΔEN1-GFP Nemowt/wt, Mx-Cre and ΔEN1-GFP Nemof/f, Mx-Cre chimeras.
(F) Micrographs of hematoxylin/eosin-stained liver and spleen sections prepared 40 days after transplantation.
(G) Kaplan-Meyer survival curve of the different recipient animals (p < 0.005).

See also Figure S8.
Caliper. Nemo<sup>ΔI</sup> mice have been described previously (Schmidt-Supprian et al., 2000). Cyld knockout mice were generated as described previously (Reiley et al., 2007). For the poly-polyC experiments, we injected 20 μg pl-pC (Amersham) per gram of body weight. All mice were kept in specific pathogen-free animal facilities. All animal procedures were approved by and carried out in accordance to the guidelines of the Institutional Animal Care and Use Committee of the New York University-School of Medicine.

Human T-ALL Samples
A total of 33 T-ALL samples and normal blood samples were obtained from the Hematology Department of Hospital de Sant Pau and the Department of Pathology of Hospital del Mar, Barcelona, Spain. All patients gave written consent to donate the blood specimen. The study was approved by the Ethics Committee of the Institution (Department of Pathology, Hospital del Mar).

Plasmids
3xk-B Luciferase and HA-k-B<sub>632-36A</sub> (Espinosa et al., 2003), k-BxK21-22R (Arezzana-Seisdedos et al., 1997), HA-TAK1K63W (Nimino-M-Tsui et al., 1999), ΔEN1-Luciferase, ΔEN1-GFP and ICN1-GFP retroviral constructs (Chiang et al., 2006; Vilimas et al., 2007), or ICN1-AQP (Bigas et al., 1998) have been previously described. Flag-Hes1 was obtained from M. Caudy (Castella et al., 1999) and used to clone Hes1 cDNA into the inducible vector. CYLD retroviral and shRNA constructs were given by A. Pfeifer (Massoumi et al., 2009). Human and mouse-specific Hes1-shRNA lentiviral constructs were purchased from Sigma (TRCN0000018989 and TRCN00000028854, respectively).

Bioluminescence Imaging
Imaging of x-B-ER-luciferase and ΔEN1-luciferase chimeras were carried out as previously described (Tseng et al., 2006).

qRT-PCR and Microarray
The primers used for RT-PCR analysis are listed in the Supplemental Experimental Procedures. qRT-PCR was carried out in LightCycler480 system using SYBR Green I Master or Probes Master kit (Roche). For microarray analysis, the data set of the genome-wide RNA expression analyses of human T-ALL cells lines treated by control peptide versus NBD peptide has been deposited in the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/); the accession number is GSE20667. RNA was labeled on hybridized to the Human U133 Plus 2.0 microarray (Affymetrix). Gene expression profiling data was first normalized using previously published robust multi-array average (RMA) algorithm implemented in RNAExpress software version 1.0.4 (http://rmaexpress.bmbolstad.com/) and log2 transformed. Then genes that are differentially expressed between NBD peptide treated and control peptide treated cells were selected using a paired two-side t test and requiring fold change ≥1.2 or ≤0.833. The multiple comparison correction was carried out using the approach of (Reiner et al., 2003) with FDR threshold equal to 0.10. The application of the above procedure resulted in 387 genes (331 oligonucleotide probes).

Quantitative DNA Methylation Analysis
DNA methylation analysis was carried out using the EpiTYPER system from Sequenom (San Diego, CA). The EpiTYPER assay is a tool for the detection and quantitative analysis of DNA methylation using base-specific cleavage of bisulfite-treated DNA and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Specific PCR primers for bisulfite-converted DNA were designed using the EpiDesigner software (www.epidesigner.com), for the entire CpG island of the genes of interest. T7-promoter tags are added to the reverse primer to obtain a product that can be in vitro transcribed, and a 10-mer tag is added to the forward primer to balance the PCR conditions. Primer sequences, target chromosomal sequence, and EpiTYPER-specific tags, are available on request. A detailed description of the protocol used can be found at the Supplemental Experimental Procedures.

Statistical Analysis
Student’s t test was carried out to assess the significance of expression levels. These data are presented as mean ± SD.

ACKNOWLEDGMENTS
We are grateful to the NYU Flow Facility for expert cell sorting, the NYU Cancer Institute Genomics Facility for help with micro-array processing, and the Meruelo Lab (NYU) for animal imaging. Adriana Heguy and the Geoffrey Beene Translational Oncology Core for assistance with sequencing and methylation analysis. Drs. T. Look and H. von Boehmer for gene expression database sharing. Drs. M. Schmidt-Supprian and A. Klinakis for valuable animal model advice. M. Caudy (Cornell University), A. Pfeifer (University of Bonn), M. Karin (UCSD), A. Gerutti (IMIM), R. Kageyama (Kyoto University), and R. Gimeno (Research Institute Hospital Vall d’Hebron) for valuable reagents and BAYER for providing the BAY65-1185. We thank C. Recasens, J. Gonzalez (IMIM), Phlmo Oh, and Camille Lobry (NYU) for experimental advice, F. Torres (UAB) for statistical analysis. J.G., T.D., and V.R. are recipients of FPI (BES-2008-005708), FPU (AP2008-01883), and FIMIMPredoctoral fellowship, respectively. L.E. is an investigator at the Carlos III program and, S.C. is supported by the Hope Street Kids Foundation. This work was supported by Instituto de Salud Carlos III Grant PI081809 and Fundación Mutua Madrileña to L.E., by MEC2007-60080 and RTICCS/FEDER (RD06/0020/0098) to A.B., by the National Institutes of Health grants R01CA133379, R01CA105129, R01CA149655, R21CA141399 (to I.A.), R01LM007948, 1UL1RR029893 (to A.S.), the American Cancer Society (RSG0806801 to I.A.), the Irma T. Hirschl Trust, The Dana Foundation, The Mallinckrodt Foundation, the Alex’s Lemonade Stand Foundation, The Leukemia and Lymphoma Society (TRP grant to I.A.), and the Gabrielle’s Angels Foundation (P.L.L. and I.A.). I.A. is an Howard Hughes Medical Institute Early Career Scientist.

Received: February 12, 2010

Revised: June 4, 2010

Accepted: July 26, 2010

Published: September 13, 2010

REFERENCES


Cancer Cell 18, 268–281, September 14, 2010 ©2010 Elsevier Inc. 279


